gc catalyst biosciences
Scope
Date
~
-
IPOs
SK Bioscience debuts strong, up 160% from IPO price
SK Bioscience Co., a spin-off from the vaccine division of SK Chemicals, posted a strong debut on Kospi on Mar. 18, closing at 169,000 won a share, ...
Mar 18, 2021 (Gmt+09:00)
language -
IPOs
SK Bioscience IPO draws record-high demand from retail investors
South Korean vaccine maker SK Bioscience Co. has set a new record for initial public offering demand, raising around 63.6 trillion won ($56 billio...
Mar 11, 2021 (Gmt+09:00)
language -
IPOs
SK Bioscience’s $1.3 bn IPO generates $10 mn in underwriting fees
The initial public offering of SK Bioscience Co. was priced at the upper end of its price band of 65,000 won ($57.3) per share on Monday to raise 1....
Mar 08, 2021 (Gmt+09:00)
-
IPOs
SK Bioscience attracts NPS, GIC in successful bookbuilding
South Korea-based SK Bioscience Co. has successfully concluded the bookbuilding for its initial public offering, attracting institutional investors ...
Mar 05, 2021 (Gmt+09:00)
language -
COVID-19
SK Bioscience eyes $900 mn annual sales from vaccine business
South Korea’s SK Bioscience Co. is looking to post 1 trillion won ($900 million) in annual revenue from its vaccine business as the biopharmac...
Feb 23, 2021 (Gmt+09:00)
language -
IPOs
Controversy surrounds SK Bioscience’s $1 bn IPO valuation
SK Bioscience Co., a spin-off of SK Chemicals Co.'s vaccine division, is set to list on the South Korean stock exchange on March 18 to raise up to $...
Feb 09, 2021 (Gmt+09:00)
-
IPOs
SK Bioscience aims for March listing; enterprise value may reach $4.5 bn
South Korea-based SK Bioscience Co. is planning its trading debut next month on the country's main bourse, Kospi. The company's enterprise value is ...
Feb 08, 2021 (Gmt+09:00)
-
Cell therapy
GC Lab Cell, Artiva ink $1.9 bn deal with MSD
South Korea-based biotechnology company Green Cross Lab Cell Corp. (GC Lab Cell) and its US-based subsidiary have inked a $1.9 billion deal to expor...
Jan 29, 2021 (Gmt+09:00)
-
IPOs
SK Bioscience begins listing process; enterprise value near $3 bn
South Korea’s SK Bioscience Co., set to enter clinical trials for its COVID-19 vaccine candidates, is expected to list on the Seoul main bours...
Dec 03, 2020 (Gmt+09:00)
-
COVID-19
SK Bioscience wins COVID-19 vaccine manufacturing order from US firm
SK Bioscience Co. Ltd. has secured a contract manufacturing organization (CMO) order for a new coronavirus vaccine candidate under development by the ...
Aug 14, 2020 (Gmt+09:00)